Jounce Therapeutics, Inc. (JNCE)
Market Cap | 96.46M |
Revenue (ttm) | 82.00M |
Net Income (ttm) | -50.92M |
Shares Out | 52.14M |
EPS (ttm) | -0.99 |
PE Ratio | n/a |
Forward PE | 19.46 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,284,590 |
Open | 1.84 |
Previous Close | 1.84 |
Day's Range | 1.84 - 1.86 |
52-Week Range | 0.58 - 7.94 |
Beta | 0.63 |
Analysts | Buy |
Price Target | 3.40 (+83.78%) |
Earnings Date | May 3, 2023 |
About JNCE
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811... [Read more]
Financial Performance
In 2022, JNCE's revenue was $82.00 million, an increase of 204.75% compared to the previous year's $26.91 million. Losses were -$50.92 million, -43.97% less than in 2021.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for JNCE stock is "Buy." The 12-month stock price forecast is $3.4, which is an increase of 83.78% from the latest price.
News

Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.

JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash ...

Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pre...

Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?
Jounce Therapeutics (NASDAQ: JNCE) stock is climbing higher on Wednesday after getting an unexpected acquisition bid from Concentra Biosciences. That acquisition offer has Concentra Biosciences seeki...

Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

Jounce Therapeutics stock bounces after saying only 1.4% of its cash was in an SVB operating account
Shares of Jounce Therapeutics Inc. JNCE, -6.09% bounced 6.6% in premarket trading Monday, after the immunotherapy company said only about $2.6 million, or 1.4% of its total cash and cash equivalents w...

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Jounce Therapeutics, Inc. - JNCE
NEW YORK , Feb. 27, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm r...

JOUNCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Jounce Therapeutics, Inc. - JNCE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Jounce Therape...

Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?
Jounce Therapeutics (NASDAQ: JNCE) stock is on the rise Thursday after the company revealed merger plans with Redx Pharma . Jounce Therapeutics and Redx Pharma will undergo a merger with an all-stock...

JNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Jounce Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Jounce Therapeutics, Inc. (NASDAQ: JNCE) and Redx Pharma is fair to Jounce shareholders...

Redx and Jounce Announce Recommended Business Combination
Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease

Jounce Therapeutics Announces Restructuring
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Jounce Therapeutics (NASDAQ: JNCE) stock jumped after it sold rights to a cancer drug to Gilead Sciences (NASDAQ: GILD). Shares were trading as high as $1.30 in the pre-market, after closing under 7...

Gilead buys out rights to cancer therapy from Jounce for $67 mln
Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.

Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug
Jounce Therapeutics Inc. JNCE, -6.66% shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. GILD, +0.31% would completely acquire rights to an...

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- -- Agreement Covers Buyout of Remaining Financial Oblig...

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (forme...

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) -

Jounce Therapeutics Reports Third Quarter 2022 Financial Results
- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress -

Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and pred...

Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
- Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 -